Skip to main content
HARBIN GLORIA PHARMACEUTICALS Co., LTD logo

HARBIN GLORIA PHARMACEUTICALS Co., LTD — Investor Relations & Filings

Ticker · 002437 ISIN · CNE100000QG8 LEI · 300300K1ZDAXM6M73U33 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,133 across all filing types
Latest filing 2025-10-13 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002437

About HARBIN GLORIA PHARMACEUTICALS Co., LTD

https://www.gloria.cc

Harbin Gloria Pharmaceuticals Co., Ltd. focuses on the research, development, manufacturing, and commercialization of diverse pharmaceutical products. The company specializes in therapeutic areas including cardiovascular and cerebrovascular diseases, orthopedics, oncology, and metabolic disorders. Its portfolio comprises chemical drugs, biological products, and specialized injections, with key products such as Alprostadil and Deer Melon Polypeptide. The organization prioritizes technological innovation through a dedicated R&D infrastructure aimed at developing both generic and innovative medications. It maintains multiple production facilities and an extensive distribution network to supply healthcare solutions for chronic and acute conditions.

Recent filings

Filing Released Lang Actions
第七届董事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is titled as a resolution announcement from the company's seventh board of directors meeting. It details decisions made by the board, including approval of guarantee management system revisions, guarantees for bank credit applications, stock incentive plan conditions, and adjustments to entrusted financial management limits. The document includes voting results and references to disclosures on official media but does not contain financial statements or detailed financial analysis. It is a formal announcement of board meeting resolutions rather than a full management report or financial report. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on board decisions, not a full report or regulatory filing.
2025-10-13 Chinese
关于2024年限制性股票激励计划之预留授予部分第一个限售期解除限售事宜的法律意见书
Audit Report / Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the lifting of restrictions on a portion of restricted stock under a 2024 stock incentive plan of Harbin Yuheng Pharmaceutical Co., Ltd. It discusses the legal compliance, approvals, and conditions met for the first unlocking period of reserved stock grants. The document is a standalone legal opinion related to a stock incentive plan and does not contain financial statements or earnings data. It is not an announcement of a report publication but a substantive legal opinion. This fits the category of Audit Report / Information (AR), which includes standalone audit or legal compliance reports related to company activities but excludes full annual or interim reports. Therefore, the appropriate classification is AR with high confidence. FY 2024
2025-10-13 Chinese
关于2024年限制性股票激励计划预留授予部分第一个限售期解除限售条件成就的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Harbin Yuheng Pharmaceutical Co., Ltd. regarding the achievement of the first unlocking condition of the 2024 restricted stock incentive plan reserved grant portion. It details the number of shares unlocked, the approval process, legal opinions, and compliance with regulatory requirements. The document is a formal disclosure about the lifting of restrictions on previously granted restricted stock, including board resolutions and legal opinions. It does not contain financial statements or detailed financial performance data, nor is it a transcript, presentation, or report. It is a regulatory announcement about stock incentive plan conditions being met and shares becoming unrestricted. This fits the category of Regulatory Filings (RNS) as it is a compliance disclosure related to stock incentive plans and share restrictions being lifted, not a full report or financial statement.
2025-10-13 Chinese
关于为全资下属公司申请银行综合授信提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Harbin Yuheng Pharmaceutical Co., Ltd. regarding the provision of guarantees for bank comprehensive credit applications by its wholly-owned subsidiaries. It includes detailed financial data of the subsidiaries, descriptions of the guarantee amounts, terms, and board opinions on the guarantees. The document references a board meeting resolution and compliance with stock exchange listing rules. It is not a full financial report, audit report, or earnings release, but rather a specific announcement about financing-related guarantees. The document length is about 3,112 characters, which is relatively short and focused on a specific financing guarantee event. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as guarantees for bank credit.
2025-10-13 Chinese
对外担保管理制度（2025年10月）
Governance Information Classification · 95% confidence The document is titled '哈尔滨誉衡药业股份有限公司 对外担保管理制度' which translates to 'Harbin Yuheng Pharmaceutical Co., Ltd. External Guarantee Management System'. It is a detailed internal policy document outlining the rules, procedures, responsibilities, and risk management related to the company's external guarantees (担保). The content includes definitions, approval processes, risk controls, responsibilities, and penalties related to external guarantees. There is no indication that this is a financial report, audit report, earnings release, or any form of regulatory filing. It is a governance-related document detailing internal rules and procedures for managing external guarantees. Therefore, it fits best under Governance Information (CGR). The document length is over 6000 characters, so it is not a brief announcement or notice but a substantive policy document.
2025-10-13 Chinese
董事会薪酬与考核委员会关于2024年限制性股票激励计划预留授予部分第一个限售期解除限售条件成就的核查意见
Remuneration Information Classification · 95% confidence The document is a formal opinion from the company's Remuneration and Assessment Committee regarding the verification of conditions for lifting restrictions on a portion of restricted stock awards under the 2024 stock incentive plan. It references compliance with stock exchange listing rules and company regulations, and it discusses approval for lifting restrictions on shares for certain incentive recipients. This content relates to executive compensation and stock incentive plans, which falls under remuneration information. The document is not a full report but a committee opinion on compensation matters, so it fits best under Remuneration Information (DEF 14A). The document length is short and focused on compensation, not a full annual or interim report or other categories.
2025-10-13 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.